These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 29070066)

  • 21. Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease.
    Cummings JL; Miller BL; Christensen DD; Cherry D
    CNS Spectr; 2008 Feb; 13(2 Suppl 2):1-20; quiz 22. PubMed ID: 18264030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
    Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
    Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
    Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
    J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent developments in Alzheimer's disease therapeutics.
    Rafii MS; Aisen PS
    BMC Med; 2009 Feb; 7():7. PubMed ID: 19228370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New and emerging treatments for Alzheimer's disease.
    Corbett A; Ballard C
    Expert Opin Emerg Drugs; 2012 Jun; 17(2):147-56. PubMed ID: 22439621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Navigating the future of Alzheimer's care in Ireland - a service model for disease-modifying therapies in small and medium-sized healthcare systems.
    Leroi I; Dolphin H; Dinh R; Foley T; Kennelly S; Kinchin I; O'Caoimh R; O'Dowd S; O'Philbin L; O'Reilly S; Trepel D; Timmons S
    BMC Health Serv Res; 2024 Jun; 24(1):705. PubMed ID: 38840115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Alzheimer's disease therapeutics.
    Rafii MS
    J Alzheimers Dis; 2014; 42 Suppl 4():S545-9. PubMed ID: 25079804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project.
    Ritchie K; Ropacki M; Albala B; Harrison J; Kaye J; Kramer J; Randolph C; Ritchie CW
    Alzheimers Dement; 2017 Feb; 13(2):186-195. PubMed ID: 27702619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
    Cummings J
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
    Knopman DS; Haeberlein SB; Carrillo MC; Hendrix JA; Kerchner G; Margolin R; Maruff P; Miller DS; Tong G; Tome MB; Murray ME; Nelson PT; Sano M; Mattsson N; Sultzer DL; Montine TJ; Jack CR; Kolb H; Petersen RC; Vemuri P; Canniere MZ; Schneider JA; Resnick SM; Romano G; van Harten AC; Wolk DA; Bain LJ; Siemers E
    Alzheimers Dement; 2018 Apr; 14(4):563-575. PubMed ID: 29653607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.
    Olsson B; Schott JM; Blennow K; Zetterberg H
    Expert Rev Neurother; 2017 Aug; 17(8):767-775. PubMed ID: 28604243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
    Tamaoka A
    Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for Alzheimer's disease.
    Sonnen JA; Keene CD; Montine KS; Li G; Peskind ER; Zhang J; Montine TJ
    Expert Rev Neurother; 2007 Aug; 7(8):1021-8. PubMed ID: 17678497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease.
    Kodosaki E; Zetterberg H; Heslegrave A
    Expert Rev Mol Diagn; 2023; 23(12):1153-1165. PubMed ID: 38018372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
    Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H
    Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug treatments in Alzheimer's disease.
    Briggs R; Kennelly SP; O'Neill D
    Clin Med (Lond); 2016 Jun; 16(3):247-53. PubMed ID: 27251914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.